Dr. Advani Discusses CD30 as a Target in ALCL

Name: Dr. Advani Discusses CD30 as a Target in ALCL
Uploaded: 2013-04-18T12:30:51.000Z
Description: Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses targeting CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma.

April 18, 2013

Ranjana Advani, MD

Video

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses targeting CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma (ALCL).

The expression of CD30 in ALCL makes it attractive to study for targeted therapies, Advani says. The antibody drug conjugate brentuximab vedotin targets CD30 and is approved by the FDA for relapsed or refractory ALCL. The agent has demonstrated an overall response rate in excess of 80%, including some extremely durable responses.